SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer

Non-small cell lung cancers with inactivating SMARCA4 mutations are currently undruggable. Here, the authors show that the absence of SMARCA4/2 reduces chromatin accessibility at the CCND1 locus, leading to a subsequent reduction in cyclin D1 expression, which promotes vulnerability of these cancers...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yibo Xue, Brian Meehan, Zheng Fu, Xue Qing D. Wang, Pierre Olivier Fiset, Ralf Rieker, Cameron Levins, Tim Kong, Xianbing Zhu, Geneviève Morin, Lashanda Skerritt, Esther Herpel, Sriram Venneti, Daniel Martinez, Alexander R. Judkins, Sungmi Jung, Sophie Camilleri-Broet, Anne V. Gonzalez, Marie-Christine Guiot, William W. Lockwood, Jonathan D. Spicer, Abbas Agaimy, William A. Pastor, Josée Dostie, Janusz Rak, William D. Foulkes, Sidong Huang
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2019
Materias:
Q
Acceso en línea:https://doaj.org/article/f919a450f672493c812a00c6c5045ab6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Non-small cell lung cancers with inactivating SMARCA4 mutations are currently undruggable. Here, the authors show that the absence of SMARCA4/2 reduces chromatin accessibility at the CCND1 locus, leading to a subsequent reduction in cyclin D1 expression, which promotes vulnerability of these cancers to CDK4/6 inhibition.